| Fiscal Month | 3月 |
|---|---|
| Established | 1937.3 |
| Listed | 1970.10 |
| Headquarters | 536-8523 大阪市城東区森之宮2-3-11 |
| Phone | 06-6969-1131 |
| Employees | <26.3> 1,374名(41.2歳) [年]605万円 |
| URL | https://www.fuso-pharm.co.jp/ |
| Bank | 三井住友,三井住友信,りそな,三菱Ｕ,北陸 |
| Supplier | 富田製薬 |
| Customer | スズケン |
| Business Segments | 医薬品100,不動産0 <26.3> |
| Foreign Ownership | 2.3% |
| Floating Shares | 32.5% |
| Investment Fund | 1.9% |
| Specific Shares | 41.1% |
| Market Cap Ranking | 医薬品 時価総額順位 28/34社 |
基本情報
人工腎臓用透析剤・補液が主軸の製薬中堅、透析剤は国内シェア５割。後発薬や製造受託も展開
特色【続落】腎・透析剤堅調と薬価小幅引き上げ奏功、一部後発薬の大幅減を補う。中東情勢に伴う原資材の年内高騰織り込み原価率が悪化、販管費も運送費など増加痛い。営業益続落。営業外支払手数料等増。
【強化布石】主力透析剤は６月にボトルタイプ製剤投入、販売テコ入れシェア向上の第一歩に。26年末の岡山第２工場着工前に資金手当てへ134億円の協調融資契約。
【時価総額増加倍率】0.21倍
926億円(1991.1.4)
【会社業績修正】上方1下方0
経常益÷期初会社予想1.1倍
業績・指標・配当
| Period | Type | Revenue(M¥) | Op.Profit(M¥) | Net Income(M¥) | Op.Margin(%) | Net Margin(%) | EPS(¥) | Div(¥) |
|---|---|---|---|---|---|---|---|---|
| 会27.3予 | Fcst | 63,200 | 2,000 | 1,300 | 3.2% | 2.1% | -- | （26.5.12発表） |
| 単22.3 | Act | 49,632 | 1,924 | 1,483 | 3.9% | 3.0% | 169.1 | 60 |
| 単23.3 | Act | 51,015 (+2.8%) | 2,206 (+14.7%) | 1,605 (+8.2%) | 4.3% | 3.1% | 183.1 (+8.3%) | 70 (+16.7%) |
| 単24.3 | Act | 55,407 (+8.6%) | 1,964 (-11.0%) | 1,377 (-14.2%) | 3.5% | 2.5% | 160 (-12.6%) | 70 (0.0%) |
| 単25.3 | Act | 60,563 (+9.3%) | 4,131 (+110.3%) | -3,288 (-338.8%) | 6.8% | -5.4% | -385 (-340.6%) | 82 (+17.1%) |
| 単25.4～9 | Int | 31,229 | 1,247 | 831 | 4.0% | 2.7% | 97.4 | 45 |
| 単26.3 | Act | 62,307 (+2.9%) | 2,639 (-36.1%) | 2,011 (+161.2%) | 4.2% | 3.2% | 235.6 (+161.2%) | 90 (+9.8%) |
| 単26.4～9予 | Fcst,Int | 31,500 (+0.9%) | 800 (-35.8%) | 500 (-39.8%) | 2.5% | 1.6% | 58.6 (-39.8%) | 45 (0.0%) |
| 単27.3予 | Fcst | 63,200 (+1.4%) | 2,000 (-24.2%) | 1,300 (-35.4%) | 3.2% | 2.1% | 152.3 (-35.4%) | 90 (0.0%) |
| 単28.3予 | Fcst | 64,500 (+3.5%) | 1,800 (-31.8%) | 1,300 (-35.4%) | 2.8% | 2.0% | 152.3 (-35.4%) | 90 (0.0%) |
| Period | 単26.3 |
|---|---|
| Total Assets (M¥) | 90,323 |
| Equity (M¥) | 35,058 |
| Equity Ratio | 38.8% |
| Capital (M¥) | 10,758 |
| Retained Earnings (M¥) | 13,881 |
| Interest Bearing Debt (M¥) | 28,462 |
| ROE | 5.9% 予3.7% |
| ROA | 2.2% 予1.4% |
| Operating CF (M¥) | -6,224 |
| Investing CF (M¥) | -1,515 |
| Financing CF (M¥) | 6,321 |
| Cash (M¥) | 4,846 |
| CapEx | 1,570 予9925 |
| Depreciation | 2,618 予2503 |
| R&D Expense | 2,013 予2000 |
| BPS (¥) | 4,107 / - |
| Period | Amount | Forecast |
|---|---|---|
| 24.3 | 35 | |
| 24.9 | 40 | |
| 25.3 | 42 | |
| 25.9 | 45 | |
| 26.3 | 45 | |
| 26.9予 | 45 | Yes |
| 27.3予 | 45 | Yes |
株主・役員構成
| Name | Shares (Ratio) |
|---|---|
| 自社（自己株口） | 91(9.6) |
| ぶどう協和会 | 59(6.3) |
| 日本マスター信託口 | 56(5.9) |
| 敷島振興 | 45(4.7) |
| 自社従業員持株会 | 32(3.4) |
| 三井住友銀行 | 27(2.9) |
| 三井住友信託銀行 | 24(2.5) |
| 戸田幹雄 | 17(1.8) |
| 日本生命保険 | 15(1.6) |
| 中尾薬品 | 15(1.6) |
| Title | Name | Outside |
|---|---|---|
| 社長 | 戸田 幹雄 | |
| 専務 | 戸田 幹洋 | |
| 取締 | 伊藤 雅教 | |
| 取締 | 大谷 英樹 | |
| 取締 | 柏木 孝 | * |
| 取締 | 渡部 靖彦 | * |
| 取締 | 池野 由香里 | * |
| 常勤監査 | 桑田 順司 | |
| 監査 | 青本 悦男 | * |
| 監査 | 楢崎 隆章 | * |
No PDF available for the selected report.
この銘柄のEDINETレポートが見つかりませんでした。